Positive News Sentiment NASDAQ:SGTX Sigilon Therapeutics - SGTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sigilon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.72 -0.01 (-1.38%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.71▼$0.7450-Day Range$0.29▼$0.7452-Week Range$0.29▼$1.90Volume29,503 shsAverage Volume622,372 shsMarket Capitalization$23.22 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Sigilon Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside738.8% Upside$6.00 Price TargetShort InterestHealthy0.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.60) to ($1.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.52 out of 5 starsMedical Sector127th out of 1,053 stocksPharmaceutical Preparations Industry53rd out of 519 stocks 3.5 Analyst's Opinion Consensus RatingSigilon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Sigilon Therapeutics has a forecasted upside of 738.8% from its current price of $0.72.Amount of Analyst CoverageSigilon Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.73% of the float of Sigilon Therapeutics has been sold short.Short Interest Ratio / Days to CoverSigilon Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sigilon Therapeutics has recently decreased by 5.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSigilon Therapeutics does not currently pay a dividend.Dividend GrowthSigilon Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SGTX. Previous Next 3.8 News and Social Media Coverage News SentimentSigilon Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.Search Interest6 people have searched for SGTX on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Sigilon Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sigilon Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of Sigilon Therapeutics is held by insiders.Percentage Held by Institutions52.20% of the stock of Sigilon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Sigilon Therapeutics are expected to grow in the coming year, from ($1.60) to ($1.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sigilon Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sigilon Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSigilon Therapeutics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sigilon Therapeutics (NASDAQ:SGTX) StockSigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More Receive SGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SGTX Stock News HeadlinesJanuary 19, 2023 | msn.comWhy Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving PremarketNovember 12, 2022 | finance.yahoo.comSigilon Therapeutics Third Quarter 2022 Earnings: Beats ExpectationsFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.November 10, 2022 | finanznachrichten.deSigilon Therapeutics, Inc.: Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsNovember 10, 2022 | finance.yahoo.comSigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsNovember 10, 2022 | finance.yahoo.comSigilon Therapeutics, Inc. (SGTX) Reports Q3 Loss, Tops Revenue EstimatesSeptember 24, 2022 | finance.yahoo.comDelix Therapeutics Expands World-Class Team with First Head of R&DSeptember 23, 2022 | benzinga.comAspect Biosystems Appoints Three New Board MembersFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.August 5, 2022 | finance.yahoo.comSigilon Therapeutics, Inc. (SGTX) Reports Q2 Loss, Tops Revenue EstimatesAugust 4, 2022 | finance.yahoo.comSigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsMay 14, 2022 | seekingalpha.comSigilon Therapeutics GAAP EPS of -$0.43, revenue of $3.17MMay 13, 2022 | finance.yahoo.comSigilon Therapeutics Reports First Quarter 2022 Financial Results And Business HighlightsMay 13, 2022 | finance.yahoo.comSigilon Therapeutics, Inc. (SGTX) Reports Q1 Loss, Tops Revenue EstimatesApril 7, 2022 | finance.yahoo.comSigilon Therapeutics to Present at the Needham Healthcare ConferenceMarch 16, 2022 | benzinga.comLooking Into Sigilon Therapeutics's Return On Capital EmployedMarch 14, 2022 | finance.yahoo.comSigilon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business HighlightsMarch 14, 2022 | finance.yahoo.comSigilon Therapeutics, Inc. (SGTX) Reports Q4 Loss, Misses Revenue EstimatesMarch 8, 2022 | finance.yahoo.comSigilon Therapeutics to Present at the Barclays Global Healthcare ConferenceMarch 3, 2022 | finance.yahoo.comZacks Industry Outlook Highlights Catalyst Pharmaceuticals, Chinook Therapeutics, Assertio Holdings and Sigilon TherapeuticsMarch 2, 2022 | finance.yahoo.com4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging IndustryFebruary 18, 2022 | bizjournals.comYumanity cuts staff by 60%, considers a saleFebruary 7, 2022 | finance.yahoo.comBears are Losing Control Over Sigilon Therapeutics, Inc. (SGTX), Here's Why It's a 'Buy' NowJanuary 31, 2022 | finance.yahoo.comSigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium™ on Lysosomal Diseases, MPS-1 and MPS-6January 14, 2022 | nasdaq.comSigilon Therapeutics Inc Shares Fall 4.4% Below Previous 52-Week Low - Market MoverDecember 14, 2021 | finance.yahoo.comSigilon Therapeutics to lay off 40 employeesDecember 14, 2021 | markets.businessinsider.comThe Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move StocksSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SGTX Company Calendar Last Earnings11/10/2022Today2/01/2023Next Earnings (Estimated)3/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SGTX CUSIPN/A CIK1821323 Websigilon.com Phone617-336-7540FaxN/AEmployees66Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+738.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-77,310,000.00 Net Margins-444.44% Pretax Margin-444.43% Return on Equity-91.82% Return on Assets-46.23% Debt Debt-to-Equity Ratio0.31 Current Ratio2.64 Quick Ratio2.64 Sales & Book Value Annual Sales$9.60 million Price / Sales2.42 Cash FlowN/A Price / Cash FlowN/A Book Value$2.39 per share Price / Book0.30Miscellaneous Outstanding Shares32,460,000Free Float31,094,000Market Cap$23.22 million OptionableNot Optionable Beta0.14 Key ExecutivesDr. Rogerio Vivaldi Coelho M.B.A. (Age 59)M.D., MBA, Pres, CEO & Director Comp: $745.9kDr. Daniel G. Anderson Ph.D. (Age 53)Co-Founder & Member of Scientific Advisory Board Comp: $46.92kMr. Philip Ashton-Rickardt Ph.D. (Age 59)Chief Scientific Officer Comp: $445.44kDr. May Orfali M.B.A. (Age 55)M.D., Exec. VP & Chief Medical Officer Comp: $536.67kDr. Robert S. Langer Jr. (Age 74)Ph.D., Sc.D., SCD, Co-Founder & Member of Scientific Advisory Board Dr. Omid Veiseh Ph.D.Co-FounderDr. José Oberholzer M.D.Co-FounderDr. Arturo Vegas Ph.D.Co-FounderMr. Josias Fantato De Pontes M.B.A. (Age 57)Acting CFO, Sr. VP, Principal Accounting Officer & Treasurer Mr. Robert Windsor Jr.J.D., VP & Head of Investor RelationsMore ExecutivesKey CompetitorsRegulus TherapeuticsNASDAQ:RGLSSoligenixNASDAQ:SNGXIMVNASDAQ:IMVMetacrineNASDAQ:MTCRTempest TherapeuticsNASDAQ:TPSTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 54,770 shares on 11/15/2022Ownership: 0.927%Renaissance Technologies LLCSold 71,953 shares on 11/14/2022Ownership: 0.482%View All Institutional Transactions SGTX Stock - Frequently Asked Questions Should I buy or sell Sigilon Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sigilon Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SGTX shares. View SGTX analyst ratings or view top-rated stocks. What is Sigilon Therapeutics' stock price forecast for 2023? 1 Wall Street research analysts have issued twelve-month price targets for Sigilon Therapeutics' stock. Their SGTX share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next year. This suggests a possible upside of 727.9% from the stock's current price. View analysts price targets for SGTX or view top-rated stocks among Wall Street analysts. How have SGTX shares performed in 2023? Sigilon Therapeutics' stock was trading at $0.35 at the beginning of 2023. Since then, SGTX stock has increased by 107.1% and is now trading at $0.7247. View the best growth stocks for 2023 here. When is Sigilon Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023. View our SGTX earnings forecast. How were Sigilon Therapeutics' earnings last quarter? Sigilon Therapeutics, Inc. (NASDAQ:SGTX) issued its earnings results on Thursday, November, 10th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.16. The business had revenue of $4.25 million for the quarter, compared to the consensus estimate of $2.45 million. Sigilon Therapeutics had a negative trailing twelve-month return on equity of 91.82% and a negative net margin of 444.44%. When did Sigilon Therapeutics IPO? (SGTX) raised $101 million in an IPO on Friday, December 4th 2020. The company issued 5,600,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity acted as the underwriters for the IPO. What is Sigilon Therapeutics' stock symbol? Sigilon Therapeutics trades on the NASDAQ under the ticker symbol "SGTX." Who are Sigilon Therapeutics' major shareholders? Sigilon Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel Griffith Anderson and Lilly & Co Eli. View institutional ownership trends. How do I buy shares of Sigilon Therapeutics? Shares of SGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sigilon Therapeutics' stock price today? One share of SGTX stock can currently be purchased for approximately $0.72. How much money does Sigilon Therapeutics make? Sigilon Therapeutics (NASDAQ:SGTX) has a market capitalization of $23.52 million and generates $9.60 million in revenue each year. The company earns $-77,310,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. How can I contact Sigilon Therapeutics? The official website for the company is sigilon.com. The company can be reached via phone at 617-336-7540 or via email at robert.windsor@sigilon.com. This page (NASDAQ:SGTX) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.